Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III trial enrolling Initial ...
HOUSTON--(BUSINESS WIRE)--Crescent Energy Company (NYSE: CRGY) today announced actual and pro forma financial and operational results for 2021 and declared a quarterly cash dividend of $0.12 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback